The tool and method century, terentiev treatment of chronic diseases of various etiology

 

(57) Abstract:

The invention relates to the field of medicine. The proposed tool, representing the homogenate tissue parenchymal organ is the pancreas of a dog or pig or eggs Mature dog male. As well as a method of treatment of chronic diseases of various etiologies through the introduction of a specified drug in the subcutaneous fat of the lower part of the anterior abdominal wall, creating in the injection of microcera inflammation, which after maturation infiltrate opens spontaneously. Offer a tissue product with a wide spectrum of actions can be used in the treatment of inflammatory diseases of the gastrointestinal tract, respiratory, urinary system, collagenase and endocrine diseases. The invention provides a wide range of chronic diseases of different etiologies. 2 C. and 14 C.p. f-crystals, 2 tab.

The invention relates to medicine, in particular for the treatment of chronic diseases of different etiologies.

Known and used in medical practice for the treatment of chronic diseases of different etiologies lekarstvennymi drugs include for example, peptides, representing a solution in hydrochloric acid products of the enzymatic hydrolysis of the gastric mucosa of pigs; drug abomin obtained from the gastric mucosa of calves and lambs dairy of age; the drug Pancreatin obtained from the pancreas of slaughtered cattle.

These drugs are used in the treatment of diseases of the gastrointestinal tract (gastritis, gastroenteritis, enterocolitis).

Also known is a method of treatment of chronic diseases of various etiologies. Thus, in the treatment of diseases of the gastrointestinal tract drug use abomin 1 tablet during meals 3 times a day (M. D. Mashkovsky "Drugs", Vilnius, 1993, part 2, pages 54 - 55).

These drugs are primarily used in the treatment of gastrointestinal diseases.

The technical task of the present invention is to create a wide spectrum of action for the treatment of chronic diseases of different etiology, and treatment of these diseases with the help of this drug.

To solve this problem is proposed remedy represents the homogenate tissue parenchymal about the and and the homogenate tissue of the testis puberty dog male.

The tool is stored at a temperature of 0oC, in a frozen state at a temperature of -10oC or localityaware form. It is intended for the treatment of inflammatory diseases of the gastrointestinal tract - gastroduodenitis, holetsistopankreatity, hepatitis, enterocolitis; inflammatory diseases of the respiratory system, urinary system; collagenase and endocrine diseases.

Method C., Terentiev treatment of chronic diseases characterized by the fact that in subcutaneous adipose tissue, mainly in the lower part of the anterior abdominal wall, creating microeca inflammation introduction homogenate tissue parenchymal organ is the pancreas of a dog or pig or eggs Mature dog male; after maturation, the abscess opens spontaneously emitting copious quantities of pus brown. The tool is administered at a dose of 0.5 ml, and for children up to 10 years at a dose of 0.3 ml of the Tool with the introduction of defrost and warm to 37oC. treatment ranged from one to eighteen months. It reuses the homogenate was administered six months after the first injection, and the third injection of twelve months after re-introduction.

aemula treatment and prevention of diseases is to create microcasa anaerobic autoinfective, after overcoming whose body gains the ability to eliminate disease and to prevent diseases caused by autoinfective and other pathogenicity factors.

Microeca create by subcutaneous injection of a homogenate tranxenogen pancreas or eggs in the quantity of 0.2 - 0.5 ml is Preferably introduced into the lower part of the anterior abdominal wall.

Fabric preparation remain frozen after thawing it homogenized mechanically in the homogenizer and incubated for one hour in a thermostat at a temperature of 37oC. do Not exclude the possibility of saving homogenate in dried form.

Penetration autounion flora injection of tissue preparation, there is reason to believe, is hematogenous neutrophils or macrophages of the intestinal wall, which contain anaerobic bacteria or their derivatives (elementary bodies). After the introduction of the homogenate develops General and local reactions.

The beginning of the General reactions of the established microeca occurs usually after 4-6 hours after administration of the drug. The reaction manifests itself as a rise in body temperature to the chills. The duration of the reaction temperature often from 1.5 to 3.5 hours. After a total reaction becomes more visible local reaction around the site of injection in the form of hyperemia and gradually increasing infiltration. As more local reactions markedly reduced overall. Sometimes, chronic inflammatory processes, the overall reaction is prolonged due to the short-term exacerbation of the underlying disease.

In our proposed method for the treatment of inflammation at the injection of the drug lasts 6-8 days, passing the stage of maturation and resolution. At rest (lying, sitting, standing) it is not painful, the pain is felt while squeezing (flexion, trunk extension) or a push in the nidus. Patients after a day or two can perform a normal operation, except for heavy physical work. Relatively weak pain of infiltration due in part to its localization, i.e. lack of tension in soft tissues of the wall of the abdomen. After maturation, the infiltrate is opened, releasing copious amounts of brown pus. Pus is allocated within 2-3 days, after which the injection heals.

General and local reactions occur in all cases and proceed the same otlichayas the t form of the disease, its duration and age of the patient. Recovery can occur gradually and after a single dose of the drug, but more often after repeated administration (6 months) or even after the third injection (12 months after re).

Positive outcomes in the treatment of various diseases are the result of a significant increase in the overall resistance of the body and mainly from the acquisition of specific immunity to ascogenous microflora and primarily on anaerobic its representatives - bacteriodes and clostridia. They are permanent inhabitants of the gastrointestinal tract, they are characterized by a complex transformation and relationship with the mucous layer, identified the migration of microbes not only in the gut, but also in epithelial cells, the white cells of the intestinal wall. We must assume that immunity to intestinal flora in the body is produced in normal conditions (intestinal barrier), but can only be obtained parenterale in the presence of tissue biofactor, which is the native tissue of the pancreas.

The proposed method of complex microbial tissue immunization promising in the treatment and prevention of many diseases blagodaaaaren immune protection not only from anaerobic autoflora, but from various factors of pathogenicity, which many are formed in the artificially created microcare.

Thanks to these characteristics, the application of the method has shown significant efficacy in the treatment of diseases such as peritonitis, pancreatitis, acute intestinal obstruction, duodenostasis, tuberculosis. Treatment or prevention of such diseases were carried out on dogs, rabbits, rats, cats, Guinea pigs and calves.

Material for preparation of the drug was used homogenate, the pancreas of a dog or pig and testicles Mature dog male.

Significant efficacy of this method in the treatment of human diseases obtained at various intestinal diseases inflammatory nature: organs of the gastrointestinal tract (gastro-duodenitis, cholecysto-pancreatitis, hepatitis, enterocolitis, and others), respiratory system, urinary system organs. Also received positive effect in collagenoses, cancer and endocrine diseases.

The optimal dose is 0.5 ml With further increase of the dose clinical effect is not growing. For children up to 10 years optimum dose sostavlenie on the data source of immunological indexes. The drug is contraindicated in thermal condition of the patient (acute cardiovascular, respiratory, renal failure).

The shelf life when stored in the frozen state (temperature -10oC) equal to six months. The drug is stored at a temperature of 0oC remains usable within 24 hours.

therapeutic properties of the drug recovered after warming to a temperature 37,0oC for 10 minutes.

The proposed tool and method for the treatment of various chronic diseases have been widely tested in clinical practice and received a positive result (see tab. 2).

1. The treatment for chronic diseases of different etiology, characterized in that it represents the homogenate tissue parenchymal organ, xenogenous pancreas or eggs.

2. Means under item 1, characterized in that it contains the homogenate tissue of the pancreas of a dog or pig.

3. Means under item 1, characterized in that it contains the homogenate tissue of the testis of adult dogs male.

4. A tool according to any one of paragraphs.1-3, characterized in that it is stored at 0oWith in six months.

6. A tool according to any one of paragraphs.1-3, characterized in that it is stored in lyophilized form.

7. A tool according to any one of paragraphs.1-3, characterized in that it is intended for the treatment of inflammatory diseases of the gastrointestinal tract, such as gastroduodenitis, holetsistopankreatity, hepatitis, enterocolitis.

8. A tool according to any one of paragraphs.1-3, characterized in that it is intended for the treatment of inflammatory diseases of the respiratory system, urinary system.

9. A tool according to any one of paragraphs.1-3, characterized in that it is intended to ensure collagenase and endocrine diseases.

10. The method of treatment of chronic diseases of different etiology, characterized in that in subcutaneous adipose tissue, mainly in the lower part of the anterior abdominal wall, creating microeca inflammation by injection of a homogenate of tissue parenchymal organ xenogeneic pancreatic gland or testicles after puberty infiltrate it opens spontaneously emitting copious quantities of pus brown.

11. The method according to p. 10, wherein introducing the homogenate tissue of the pancreas of a dog or pig is on the floor.

13. The method according to any of paragraphs.10-12, characterized in that the homogenate was injected at a dose of 0.5 ml.

14. The method according to any of paragraphs.10-13, characterized in that the treatment ranged from one to 18 months, it reuses the homogenate was administered six months after the first injection, and the third injection twelve months after re-introduction.

15. The method according to any of paragraphs.10-12, characterized in that in the treatment of chronic diseases of children under the age of 10 years, the homogenate was injected in a dose of 0.3 ml.

16. The method according to any of paragraphs.10-14, characterized in that the homogenate before the introduction of thawed to 37oC.

 

Same patents:
The invention relates to medicine, in particular to the treatment of diseases characterized by autoimmune aggression
The invention relates to medicine and can be used for the treatment of demyelinating disorders of the CNS, mainly neyroinfektsionnyh Genesis transplantation of embryonic brain tissue

The invention relates to medicine, in particular to Oncology
The invention relates to medicine, namely neurosurgery, neurology and psychotria and can be used for examination of patients with suspected epilepsy
The invention relates to medicine and can be used in the treatment of diseases of the Central nervous system

The invention relates to medicine, in particular for cell therapy and can be used for the treatment of diseases caused by disorders of the immune system, for example, diabetes

The invention relates to medicine, traumatology

The invention relates to medicine, namely to Oncology, clinical immunology, and can be advantageously used for the treatment of cancer
The invention relates to the production of biogenic drugs and is an extract from the placenta of cows with bacteriophages, have an antimicrobial effect on the microflora of the uterus without irritation mucous membrane, designed for the treatment and prevention of postpartum diseases of female farm animal
The invention relates to medicine, namely to a method for producing a material containing beta cells of the pancreas of newborn rabbits, and transplantologists methods of treatment of diabetes, insulin dependent mainly by transplantation of beta cells, obtained using the phenomenon of migration
The invention relates to medicine, in particular to obstetrics and gynecology, and for the treatment of postpartum endometritis.
The invention relates to medicine, namely to pharmacology to wound means of broad-spectrum

The invention relates to the field of biotechnology, in particular to the production of medicines from animal products, and may find application in the production of ribonuclease pancreatic amorphous
The invention relates to medicine and Enzymology, in particular to the technology of production of the main inhibitor of the prosthesis (IPRs) trypsin, kallikrein, plasmin

The invention relates to the field of protein chemistry

The invention relates to medicine, in particular to obstetrics
The invention relates to medicine, namely to ophthalmology, and can be used for the treatment of diabetic retinopathy
The invention relates to biotechnology, in particular to a technology for basic proteinase inhibitor from the bodies of cattle

The invention relates to veterinary medicine, namely to veterinary drugs for the treatment and prevention of digestive disorders on the basis of tissue from the pancreas of pigs and broiler chickens

FIELD: medicine, anesthesiology, resuscitation, traumatology, orthopedics.

SUBSTANCE: additionally to infusion, transfusion, antibacterial therapies and measures on stabilization of osseous fragments one should introduce hordox simultaneously at the quantity of 500000 U during the 1st d after trauma, then - every 8 h per 200000 U for 2 d and before operation simultaneously at the quantity of 500000 U, then every 8 h per 200000 U for 2 d or ingitryl simultaneously at the quantity of 150 U during the 1st d after trauma to continue therapy for 2-3 d at the quantity of 150 U daily, and before operation it should be introduced simultaneously at the quantity of 150 U to continue therapy for 2-3 d at the quantity of 150 U daily. The present innovation enables to suppress excessive production of cytokines that in its turn favors prevention of pain syndrome, edema and soft tissue necrosis development in the affected limb.

EFFECT: higher efficiency of therapy.

2 ex

Up!